Semaglutide: ACHIEVE-3 Study Compares Oral Orforglipron Efficacy

By Hipa.ai Research · January 1, 2026

Synced daily from openFDA and ClinicalTrials.gov. Last sync: June 12, 2026.

A pivotal study, ACHIEVE-3, comparing the efficacy and safety of once-daily oral orforglipron with oral semaglutide in adults with type 2 diabetes, was published on 2026-01-01. This multinational, multicenter trial assessed these treatments in patients whose type 2 diabetes was inadequately controlled with metformin.

Background

Semaglutide is a well-established medication for the management of type 2 diabetes. It is available in various formulations, including oral and injectable options, and is known for its effectiveness in improving glycemic control. The comparison with orforglipron, another investigational oral agent, is significant for the evolving landscape of diabetes treatment, particularly for patients who require additional therapeutic options when metformin alone is insufficient.

Trial design

The ACHIEVE-3 study, titled 'A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin,' was a multinational, multicenter trial. It investigated the efficacy and safety of once-daily oral orforglipron in comparison to oral semaglutide. The study population included adults with type 2 diabetes whose glycemic control remained inadequate despite treatment with metformin.

What this means

The publication of the ACHIEVE-3 study provides clinicians and researchers with new data regarding the comparative performance of oral orforglipron and oral semaglutide. For patients with type 2 diabetes whose condition is not adequately controlled with metformin, understanding the efficacy and safety profiles of different oral GLP-1 receptor agonists is crucial for personalized treatment decisions. This research contributes to the growing body of evidence supporting the use of oral GLP-1 receptor agonists in diabetes management.

Source

The information regarding the ACHIEVE-3 study publication was sourced from PubMed. The details of this pivotal publication, including its title 'Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non (Lancet)', were made available on 2026-01-01 via pubmed.ncbi.nlm.nih.gov.